Zacks Small Cap Forecasts Bone Biologics Q2 Earnings

Bone Biologics Co. (NASDAQ:BBLG) – Investment analysts at Zacks Small Cap issued their Q2 2025 earnings per share estimates for Bone Biologics in a research report issued to clients and investors on Tuesday, May 13th. Zacks Small Cap analyst B. Sorensen forecasts that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Bone Biologics’ current full-year earnings is ($5.00) per share. Zacks Small Cap also issued estimates for Bone Biologics’ Q3 2025 earnings at ($0.30) EPS, Q4 2025 earnings at ($0.28) EPS, FY2025 earnings at ($1.22) EPS and FY2026 earnings at ($0.97) EPS.

Bone Biologics Trading Down 1.1%

NASDAQ:BBLG opened at $0.72 on Friday. Bone Biologics has a 52-week low of $0.57 and a 52-week high of $4.25. The business’s fifty day moving average is $0.75 and its 200 day moving average is $0.97.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.16.

Bone Biologics Company Profile

Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.